Until recently, no drug was labeled for AL amyloidosis. In 2011, the Italian Medicines Agency started a program to grant access to upfront bortezomib to patients with AL amyloidosis. All subjects were enrolled in a prospective online registry. Response was evaluated after two cycles to assess the possibility of continuing treatment. A total of 764 patients were included until 2019, and 615 were evaluable. Sixteen percent of patents had advanced (stage-IIIb) heart involvement, and 27% had severe or end-stage renal failure. Bortezomib delivery was possible in stage-IIIb patients at a reduced dose. Bortezomib discontinuation was associated with increasing age, advanced heart involvement and bi-weekly administration. Fifty-nine percent of subjects attained a hematologic response and 14% a cardiac response. Bortezomib-based therapy tends to be discontinued early in elderly patients and in advanced disease. Nevertheless, early response to therapy is possible in this challenging population.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.1971215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma.
J Patient Rep Outcomes
December 2024
Department of Symptom Research, Unit 1450, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Article Synopsis
- - The study aimed to track symptom severity in multiple myeloma (MM) patients during 16 weeks of induction therapy and identify factors that predict high symptom burden, which are often overlooked in clinical settings.
- - Researchers used a symptom inventory to categorize patients into groups with persistently high or low symptom severity, finding that severe symptoms included pain, muscle weakness, and fatigue, affecting patients' quality of life and emotional well-being.
- - Results indicated that 31% of patients experienced high-severity symptoms, with factors like baseline symptom scores and being female linked to worse outcomes, highlighting the need for better monitoring and support during therapy.
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study.
Ther Adv Hematol
October 2024
Department of Hematology, The Affiliated Hospital of Qingdao University, 1677 Wutaishan Road, Qingdao, Shandong 225009, China.
Background: Secondary myelofibrosis (SMF) is characterized by the excessive deposition of fibrous tissue on top of the primary disease, often causing clinical manifestations to be overshadowed by the primary disease. Unfortunately, current staging systems do not incorporate myelofibrosis, leading to potential treatment delays for SMF.
Objectives: To evaluate the prognosis of patients with multiple myeloma (MM) complicated with myelofibrosis.
Real World Outcome of High-Risk Multiple Myeloma: An Indian Tertiary Care Centre Experience.
Clin Lymphoma Myeloma Leuk
September 2024
Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. Electronic address:
Introduction: High risk myeloma is heterogeneous with significant variation in risk stratifications. Real world outcomes differ from controlled clinical trials and affected by socioeconomical determinants.
Material And Methods: This retrospective study was performed in a North Indian teriarty care cancer hospital.
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment.
Cancers (Basel)
September 2024
Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
Data on the outcome of octogenarian multiple myeloma (MM) patients (pts), especially if treated outside clinical studies, are scanty. : MM pts ≥ 80 years, treated at TASMC with first-line therapy between 2010 and 2023, were reviewed. Characteristics and outcomes were analyzed.
View Article and Find Full Text PDFAutologous stem cell transplantation can potentially reverse dialysis dependence in patients with myeloma: Report of two cases and practical considerations.
Natl Med J India
October 2024
Department of Pathology, Dayanand Medical College and Hospital, Tagore Nagar, Ludhiana 141001, Punjab, India.
Article Synopsis
- * Two dialysis-dependent patients underwent ASCT after partial recovery from treatment and received specific protocols, including a pre-emptive dialysis session and careful monitoring for complications.
- * Both patients showed positive outcomes post-transplant, with one being dialysis-free for 18 months and the other for 9 months before needing less frequent dialysis, indicating ASCT's potential benefits for this group despite inherent risks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!